🇺🇸 Oxaliplatin intravenous in United States

20 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Decreased Appetite — 4 reports (20%)
  2. Nausea — 3 reports (15%)
  3. Amaurosis Fugax — 2 reports (10%)
  4. Colon Cancer — 2 reports (10%)
  5. Diarrhoea — 2 reports (10%)
  6. Metastases To Liver — 2 reports (10%)
  7. Neuropathy Peripheral — 2 reports (10%)
  8. Amylase Increased — 1 report (5%)
  9. Anaemia — 1 report (5%)
  10. Anaphylactic Reaction — 1 report (5%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Oxaliplatin intravenous approved in United States?

Oxaliplatin intravenous does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Oxaliplatin intravenous in United States?

Federation Francophone de Cancerologie Digestive is the originator. The local marketing authorisation holder may differ — check the official source linked above.